Supplement Use and Behaviors of Athletes Affiliated With an Australian State-Based Sports Institute.

The authors aimed to update knowledge of the use of supplements among Australian athletes at a state-based sports institute. The authors conducted a cross-sectional survey using an online questionnaire to assess the influence of age, sports category, and scholarship category on supplement use. Of 94 completed questionnaires, 82 (87%) indicated supplements in the previous 12 months (mean = 4.9 ± 3.3). No significant difference in supplement usage rate was identified when considering age, scholarship category, or sport category. The most frequently used supplements were sports drinks (70%), caffeine (48%), protein powder (42%), and sports bars (42%). Recovery (63%), health maintenance (59%), and improved energy (50%) were the most frequently reported rationale to use supplements. Allied health professionals and credible online resources were the predominant sources of influence regarding use. However, athletes from lower scholarship categories were more likely to have social media, parents, and siblings influence usage, and age was inversely related to increased influence from parents, social media, physicians not associated with the institute, the Internet, and siblings. Older athletes and those on higher scholarships were more likely to source supplements from training facilities and sports nutrition staff outside of the institute or direct from a supplier, whereas those on lower scholarships tended to rely more on family and friends for their supplements. Findings from this study show a high prevalence of supplement use and are the first to show an influence of social media, particularly in younger athletes. Opportunities exist to optimize how athletes are informed regarding supplement use and organizational and supplement policy.

Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist.

The nonselective glucocorticoid receptor (GR) antagonist mifepristone has been approved in the U.S. for the treatment of selected patients with Cushing's syndrome. While this drug is highly effective, lack of selectivity for GR leads to unwanted side effects in some patients. Optimization of the previously described fused azadecalin series of selective GR antagonists led to the identification of CORT125134, which is currently being evaluated in a phase 2 clinical study in patients with Cushing's syndrome.

Gene-environment interactions in a mutant mouse kindred with native airway constrictor hyperresponsiveness.

We mutagenized male BTBR mice with N-ethyl-N-nitrosourea and screened 1315 of their G3 offspring for airway hyperresponsiveness. A phenovariant G3 mouse with exaggerated methacholine bronchoconstrictor response was identified and his progeny bred in a nonspecific-pathogen-free (SPF) facility where sentinels tested positive for minute virus of mice and mouse parvovirus and where softwood bedding was used. The mutant phenotype was inherited through G11 as a single autosomal semidominant mutation with marked gender restriction, with males exhibiting almost full penetrance and very few females phenotypically abnormal. Between G11 and G12, facility infection eradication was undertaken and bedding was changed to hardwood. We could no longer detect airway hyperresponsiveness in more than 37 G12 offspring of 26 hyperresponsive G11 males. Also, we could not identify the mutant phenotype among offspring of hyperresponsive G8-G10 sires rederived into an SPF facility despite 21 attempts. These two observations suggest that both genetic and environmental factors were needed for phenotype expression. We suspect that rederivation into an SPF facility or altered exposure to pathogens or other unidentified substances modified environmental interactions with the mutant allele, and so resulted in disappearance of the hyperresponsive phenotype. Our experience suggests that future searches for genes that confer susceptibility for airway hyperresponsiveness might not be able to identify some genes that confer susceptibility if the searches are performed in SPF facilities. Experimenters are advised to arrange for multigeneration constancy of mouse care in order to clone mutant genes. Indeed, we were not able to map the mutation before losing the phenotype.